Association between captopril, other antihypertensive drugs and risk of prostate cancer
2004 (English)In: The Prostate, ISSN 0270-4137, E-ISSN 1097-0045, Vol. 58, no 1, 50-56 p.Article in journal (Refereed) Published
There has been some debate on the existence of an association between hypertension, antihypertensive medications and cancer risk.
We performed a nested case-control study to assess the association between the risk of prostate cancer and the use of the angiotensin converting enzyme (ACE)-inhibitor captopril, and other antihypertensive drugs. We used data from the General Practice Research Database in UK.
We found an incidence rate of prostate cancer of 1.61 per 1,000 person-years among male patients aged 50–79 years old. Patients with a history of benign prostatic hyperplasia and/or prostatism carried a two-fold greater risk of prostate cancer than those without such antecedents. None of the other studied co-morbidities were associated with prostate cancer. We found that users of captopril had a relative risk of 0.7 (95% CI: 0.4–1.2) to develope prostate cancer. None of the other studied individual ACE-inhibitors shared a similar effect with the one observed for captopril.
No clear association was apparent between the use of antihypertensive drugs and prostate cancer. However, specific focus on users of captopril showed a lower risk of subsequent prostate cancer. Further research is needed to explore this association.
Place, publisher, year, edition, pages
2004. Vol. 58, no 1, 50-56 p.
prostate, prostasomes, prostate cancer, angiotensin-I-converting enzyme, captopril, metalloproteases
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-79652DOI: 10.1002/pros.10294PubMedID: 14673952OAI: oai:DiVA.org:uu-79652DiVA: diva2:107565